Allogene Therapeutics (ALLO) Gains from Investment Securities (2018 - 2026)
Allogene Therapeutics recorded quarterly Gains from Investment Securities of -$84000.0 in Q1 2026, up 94.41% quarter-over-quarter from -$1.5 million in Q3 2025, and up 80.24% year-over-year from -$46605.7 in Q1 2025.
Allogene Therapeutics' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at -$84000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 80.24% year-over-year to -$84000.0; the TTM figure through Mar 2026 stood at $341000.0 (up 110.46% YoY), while the FY2024 annual figure was -$4.3 million, down 161.13% from the prior year.
- Gains from Investment Securities came in at -$84000.0 for Q1 2026 at Allogene Therapeutics, up from -$1.5 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $28.2 million in Q4 2022 to a low of -$6.7 million in Q4 2024.
- A 5-year average of $2.5 million and a median of $100000.0 in 2023 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 3754.0% in 2024 and fell as far as 3111.11% in 2024.
- Allogene Therapeutics' Gains from Investment Securities stood at $28.2 million in 2022, then slumped by 75.13% to $7.0 million in 2023, then sank by 195.54% to -$6.7 million in 2024, then surged by 77.53% to -$1.5 million in 2025, then soared by 94.41% to -$84000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$84000.0, -$1.5 million, and $1.9 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Allogene Therapeutics | 521.43 Mn | 521.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84,000.00 |
| Mar 31, 2026 | -84,000.00 |
| Sep 30, 2025 | -1.50 Mn |
| Sep 30, 2025 | -1.50 Mn |
| Jun 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 1.93 Mn |
| Mar 31, 2025 | -425,000.00 |
| Mar 31, 2025 | -425,000.00 |
| Dec 31, 2024 | -6.69 Mn |
| Dec 31, 2024 | -6.69 Mn |
| Jun 30, 2024 | 3.85 Mn |
| Jun 30, 2024 | 3.85 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | -45,000.00 |
| Mar 31, 2023 | -45,000.00 |
| Dec 31, 2022 | 28.15 Mn |
| Dec 31, 2022 | 28.15 Mn |
| Sep 30, 2022 | 408,000.00 |
| Sep 30, 2022 | 408,000.00 |
| Jun 30, 2022 | -311,000.00 |
| Jun 30, 2022 | -311,000.00 |
| Mar 31, 2022 | 3.11 Mn |
| Mar 31, 2022 | 3.11 Mn |
| Dec 31, 2021 | 19.09 Mn |
| Dec 31, 2021 | 19.09 Mn |
| Sep 30, 2021 | -14.95 Mn |
| Sep 30, 2021 | -14.95 Mn |
| Jun 30, 2021 | 15.14 Mn |
| Jun 30, 2021 | 15.14 Mn |
| Mar 31, 2021 | 799,000.00 |
| Mar 31, 2021 | 799,000.00 |
| Dec 31, 2020 | 1.94 Mn |
| Dec 31, 2020 | 1.94 Mn |
| Sep 30, 2020 | 483,000.00 |
| Sep 30, 2020 | 483,000.00 |
| Jun 30, 2020 | -2.46 Mn |
| Jun 30, 2020 | -2.46 Mn |
| Dec 31, 2019 | 10.96 Mn |
| Dec 31, 2019 | 10.96 Mn |
| Sep 30, 2019 | 870,000.00 |
| Sep 30, 2019 | 870,000.00 |
| Jun 30, 2019 | 1.81 Mn |
| Jun 30, 2019 | 1.81 Mn |
| Mar 31, 2019 | 8.94 Mn |
| Mar 31, 2019 | 8.94 Mn |
| Dec 31, 2018 | 7.69 Mn |
| Dec 31, 2018 | 7.69 Mn |
| Sep 30, 2018 | 6.08 Mn |
| Sep 30, 2018 | 6.08 Mn |